glp-1 and fatty liver disease Receptor Agonists in Non-Alcoholic Disease: Current Evidence Future Perspectives Glucagon-Like Peptide-1: New Regulator in
Description
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes
Kang MW, Tangri N, Kim YC, An JN, Lee J, Li L, et al
J Cardiovasc Dev Dis
Good news
For example, in the EMPA-REG OUTCOME trial, patients randomized to receive empagliflozin experienced a significant reduction in cardiovascular death, all-cause mortality, and hospitalization for heart failure compared to placebo despite only modest differences in HbA1c between groups [22]
